IBXN.F Stock Overview
IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
IBEX Technologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.00 |
| 52 Week High | CA$1.10 |
| 52 Week Low | CA$0.56 |
| Beta | -0.045 |
| 1 Month Change | -5.71% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | 256.58% |
| 5 Year Change | 699.36% |
| Change since IPO | 960.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| IBXN.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.5% | -3.9% | -3.1% |
| 1Y | n/a | -1.8% | 20.9% |
Return vs Industry: Insufficient data to determine how IBXN.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how IBXN.F performed against the US Market.
Price Volatility
| IBXN.F volatility | |
|---|---|
| IBXN.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IBXN.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IBXN.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1972 | n/a | Paul Baehr | www.ibex.ca |
IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; collagen ELISAs for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research.
IBEX Technologies Inc. Fundamentals Summary
| IBXN.F fundamental statistics | |
|---|---|
| Market cap | US$25.98m |
| Earnings (TTM) | US$2.93m |
| Revenue (TTM) | US$5.89m |
8.9x
P/E Ratio4.4x
P/S RatioIs IBXN.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBXN.F income statement (TTM) | |
|---|---|
| Revenue | CA$8.00m |
| Cost of Revenue | CA$2.23m |
| Gross Profit | CA$5.77m |
| Other Expenses | CA$1.79m |
| Earnings | CA$3.98m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.16 |
| Gross Margin | 72.11% |
| Net Profit Margin | 49.70% |
| Debt/Equity Ratio | 0% |
How did IBXN.F perform over the long term?
See historical performance and comparison